Vertex Pharmaceuticals Incorporated: Vertex Advances VX-548 in Acute and Neuropathic Pain
VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end -
Source: finanznachrichten.de